Zoetis Inc. $ZTS Stock: Heritage Investors Management Corp Lowers Holdings

Heritage Investors Management Corp reduced its position in shares of Zoetis Inc. (NYSE:ZTS) by 8.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 186,986 shares of the company’s stock after selling 18,196 shares during the quarter. Heritage Investors Management Corp’s holdings in Zoetis were worth $13,057,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in ZTS. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Zoetis in the 3rd quarter valued at about $8,169,000. Profund Advisors LLC lifted its stake in Zoetis by 226.7% in the 3rd quarter. Profund Advisors LLC now owns 25,433 shares of the company’s stock valued at $1,776,000 after purchasing an additional 17,649 shares during the last quarter. ProShare Advisors LLC grew its holdings in Zoetis by 5.6% during the third quarter. ProShare Advisors LLC now owns 115,215 shares of the company’s stock worth $8,045,000 after purchasing an additional 6,119 shares during the period. Vise Technologies Inc. grew its holdings in Zoetis by 52.9% during the third quarter. Vise Technologies Inc. now owns 14,886 shares of the company’s stock worth $1,039,000 after purchasing an additional 5,151 shares during the period. Finally, Cidel Asset Management Inc. increased its position in Zoetis by 17.5% during the third quarter. Cidel Asset Management Inc. now owns 4,003 shares of the company’s stock worth $280,000 after buying an additional 595 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

ZTS has been the subject of a number of recent analyst reports. Citigroup cut their price objective on Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a research report on Tuesday, August 11th. BTIG Research dropped coverage on Zoetis in a report on Friday. They set a “buy” rating on the stock. UBS Group increased their price target on Zoetis from $80.00 to $85.00 and gave the company a “neutral” rating in a research note on Tuesday, October 27th. HSBC dropped their price target on Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a research note on Monday, July 6th. Finally, The Goldman Sachs Group assumed coverage on shares of Zoetis in a research report on Friday, October 16th. They set a “neutral” rating and a $74.00 price objective for the company. Six analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $93.79.

Key Headlines Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: The FDA approved Convenia RTU, a ready-to-use, single-dose antibiotic for dogs. The product could strengthen Zoetis’ companion-animal portfolio and provide an additional commercial opportunity. FDA approves Convenia RTU ahead of Q3 results for Zoetis stock
• Positive Sentiment: Analysts expect Zoetis to potentially beat consensus estimates in its upcoming third-quarter report, with the company’s earnings setup and operating trends viewed as supportive. This is an expectation, not a reported result. Zoetis expected to beat earnings estimates
• Positive Sentiment: BTIG Research assigned a “buy” view before ending its coverage of Zoetis. The endorsement may reinforce the argument that the shares are undervalued, although the end of coverage reduces the ongoing value of that analyst relationship. BTIG Research ratings
• Neutral Sentiment: Recent market commentary highlights valuation compression versus animal-health peers IDEXX Laboratories and Elanco. Livestock and international sales have partly offset weaker U.S. pet-care demand, creating a possible recovery opportunity but not yet confirming a broad business rebound. Zoetis versus IDEXX and Elanco valuation analysis
• Negative Sentiment: Investors remain cautious because lower guidance and softer U.S. pet-care demand could limit the pace of recovery, even as the new product approval and potential earnings beat provide near-term support.

Zoetis Stock Down 0.1%

ZTS opened at $79.67 on Monday. Zoetis Inc. has a fifty-two week low of $68.77 and a fifty-two week high of $144.83. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. The company has a market capitalization of $32.92 billion, a P/E ratio of 13.13, a P/E/G ratio of 1.18 and a beta of 0.67. The stock has a fifty day moving average of $75.04 and a 200-day moving average of $93.64.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. The company had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. Zoetis’s quarterly revenue was down .2% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, equities analysts expect that Zoetis Inc. will post 6.15 EPS for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, October 30th will be given a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Friday, October 30th. Zoetis’s dividend payout ratio is presently 34.93%.

About Zoetis

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company’s product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.